Pathology Laboratory Services

Serving more than 5,500 patients each day, Miraca Life Sciences is a leading, academic-caliber anatomic pathology laboratory, providing diagnostic services in the fields of breast health, dermatology, gastroenterology, hematology and urology. Building on our experience with health IT, we also offer technology solutions and consulting services to assist clinicians and centers with MIPS and other reporting requirements. In November 2017, Miraca Life Sciences was acquired by Avista Capital Partners, and we soon will roll out a new name.

Miraca Research & Development Services utilize our expertise and resources as a premier anatomic pathology commercial laboratory. Miraca’s difference is in our ability to draw upon the foundation of our commercial laboratory, to provide pathology, laboratory and data services.

We employ a talented team of leading pathologists, histologists, lab technicians, technology consultants, and other medical professionals — all driven to help provide the highest and most up-to-date levels of diagnostic quality, enhanced workflow and practice solutions possible. It’s part of our commitment: not only to scientific excellence, but to you.

Pathology Research & Publications

Our skilled team of field-specific clinical pathologists, consultants and experts work diligently to stay at the forefront of the ever-changing landscape of a pathology laboratory and health IT. As part of this diligence, we work closely with one another to provide the highest quality, academic-based research and information possible.

Recent News


November 20, 2017

Avista Capital Partners Completes Acquisition of Miraca Life Sciences

IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc.

Continue reading the press release at the Avista website.

Continue reading


October 16, 2017

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences […]

Continue reading


The Miraca support team is always available, even if it’s a quick text. I cannot stress enough how great it is to know someone is always there, especially when it came time to attest for Meaningful Use and PQRS. It was my first year attesting for our practice and was a day I initially dreaded. Kimberly Johnson and Amy Schmid helped me run reports each month to make sure our practice was on track, then came in and made attestation look easy. They are so knowledgeable. Then to top it off, we have our sales rep, Laura Richards, who is always available when we need her and happy to help. I can’t imagine our practice without EMA and our Miraca team. Thank you for going above and beyond.
— Kimberly J. Wonderlich, MD,
Wonderlich Dermatology, Fairbanks, Alaska


READ MORE

Featured Subspecialty Expert


Rajal B. Shah, MD

Vice President, Medical Director, Urologic Pathology

more